Phase 1b/2a Study of Galunisertib, a Small Molecule Inhibitor of Transforming Growth Factor-Beta Receptor I, in Combination With Standard Temozolomide-Based Radiochemotherapy in Patients With Newly Diagnosed Malignant Glioma

Investigational New Drugs - Netherlands
doi 10.1007/s10637-020-00910-9
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

A Phase 1b Study of Transforming Growth Factor-Beta Receptor I Inhibitor Galunisertib in Combination With Sorafenib in Japanese Patients With Unresectable Hepatocellular Carcinoma

Investigational New Drugs
OncologyPharmacology
2018English

Phase II Study of SU5416, a Small Molecule Vascular Endothelial Growth Factor Tyrosine Kinase Receptor Inhibitor, in Patients With Refractory Multiple Myeloma

Clinical Cancer Research
Cancer ResearchOncology
2004English

Clinical Phase I Study With an Insulin-Like Growth Factor-1 Receptor Inhibitor: Experiences in Patients With Squamous Non-Small Cell Lung Carcinoma

Acta Oncologica
Nuclear MedicineRadiologyHematologyOncologyMedicineImaging
2010English

A Phase I/Ii Study of Lomustine and Temozolomide in Patients With Cerebral Metastases From Malignant Melanoma

British Journal of Cancer
Cancer ResearchOncology
2006English

Phase I Study of SU5416, a Small Molecule Inhibitor of the Vascular Endothelial Growth Factor Receptor (VEGFR) in Refractory Pediatric Central Nervous System Tumors

Pediatric Blood and Cancer
OncologyChild HealthHematologyPerinatologyMedicinePediatrics
2009English

Phase I Study of Sunitinib and Irinotecan for Patients With Recurrent Malignant Glioma

Journal of Neuro-Oncology
Cancer ResearchOncologyNeurology
2011English

Nimotuzumab Prolongs Survival in Patients With Malignant Gliomas: A Phase I/Ii Clinical Study of Concomitant Radiochemotherapy With or Without Nimotuzumab

Experimental and Therapeutic Medicine
MedicineCancer ResearchImmunologyMicrobiology
2012English

Phase I Study of Temozolomide in Paediatric Patients With Advanced Cancer

British Journal of Cancer
Cancer ResearchOncology
1998English

The Insulin-Like Growth Factor-I Receptor Inhibitor Figitumumab (CP-751,871) in Combination With Docetaxel in Patients With Advanced Solid Tumours: Results of a Phase Ib Dose-Escalation, Open-Label Study

British Journal of Cancer
Cancer ResearchOncology
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy